科伦博泰生物(06990.HK)核心产品博度曲妥珠单抗新药申请获受理

阿斯达克财经
07 Jan

科伦博泰生物-B(06990.HK) 公布,靶向人类表皮生长因子受体2(HER2)的抗体药物偶联物(ADC)博度曲妥珠单抗的新药申请已获中国国家药品监督管理局药品审评中心受理,用于既往至少接受过一种抗HER2治疗的HER2阳性不可切除或转移性乳腺癌成人患者的治疗。博度曲妥珠单抗是公司研发的创新HER2 ADC。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10